XLO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Xilio Therapeutics Inc (XLO) is not a strong buy for a beginner, long-term investor at this time. The technical indicators show a bearish trend, and there are no significant positive catalysts or trading signals to suggest immediate upside potential. While the company has shown impressive revenue growth in its latest quarter, its negative net income and declining EPS are concerning for long-term stability. Additionally, there is no recent congress trading data or influential figure activity to support a buy decision.
The MACD is slightly positive but contracting, RSI is neutral at 38.36, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 0.545, with resistance at 0.573 and support at 0.518. Overall, the technical indicators suggest a bearish trend.
The company has shown significant revenue growth in Q3 2025, up 742.51% YoY, and gross margin remains at 100%.
The company continues to report negative net income (-$16.29M) and declining EPS (-50% YoY). Bearish technical indicators and lack of significant insider or hedge fund activity further weigh on the stock.
In Q3 2025, revenue increased significantly to $19.07M (up 742.51% YoY), but net income remains negative at -$16.29M (improved 16.17% YoY). EPS dropped to -0.11 (-50% YoY), and gross margin stayed at 100%.
No recent analyst rating or price target changes available.
